These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 10824626)
1. Investigations of the metabolites of the trypanocidal drug melarsoprol. Keiser J; Ericsson O; Burri C Clin Pharmacol Ther; 2000 May; 67(5):478-88. PubMed ID: 10824626 [TBL] [Abstract][Full Text] [Related]
2. Determination of the trypanocidal drug melarsoprol and its conversion products in biological fluids with HPLC-ICPMS/ESMS. Raber G; Raber T; Raml R; Murko M; Magnes C; Francesconi KA Talanta; 2013 Nov; 116():876-81. PubMed ID: 24148488 [TBL] [Abstract][Full Text] [Related]
3. Genotypic and phenotypic characterization of Trypanosoma brucei gambiense isolates from Ibba, South Sudan, an area of high melarsoprol treatment failure rate. Maina N; Maina KJ; Mäser P; Brun R Acta Trop; 2007; 104(2-3):84-90. PubMed ID: 17765860 [TBL] [Abstract][Full Text] [Related]
4. The phenomenon of treatment failures in Human African Trypanosomiasis. Brun R; Schumacher R; Schmid C; Kunz C; Burri C Trop Med Int Health; 2001 Nov; 6(11):906-14. PubMed ID: 11703845 [TBL] [Abstract][Full Text] [Related]
5. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness. Bisser S; N'Siesi FX; Lejon V; Preux PM; Van Nieuwenhove S; Miaka Mia Bilenge C; Būscher P J Infect Dis; 2007 Feb; 195(3):322-9. PubMed ID: 17205469 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic properties of the trypanocidal drug melarsoprol. Burri C; Baltz T; Giroud C; Doua F; Welker HA; Brun R Chemotherapy; 1993; 39(4):225-34. PubMed ID: 8391966 [TBL] [Abstract][Full Text] [Related]
7. Discrepancy in plasma melarsoprol concentrations between HPLC and bioassay methods in patients with T. gambiense sleeping sickness indicates that melarsoprol is metabolized. Bronner U; Brun R; Doua F; Ericsson O; Burri C; Keiser J; Miézan TW; Boa YF; Rombo L; Gustafsson LL Trop Med Int Health; 1998 Nov; 3(11):913-7. PubMed ID: 9855405 [TBL] [Abstract][Full Text] [Related]
8. The role of Trypanosoma brucei MRPA in melarsoprol susceptibility. Alibu VP; Richter C; Voncken F; Marti G; Shahi S; Renggli CK; Seebeck T; Brun R; Clayton C Mol Biochem Parasitol; 2006 Mar; 146(1):38-44. PubMed ID: 16343658 [TBL] [Abstract][Full Text] [Related]
9. [Arsenical-induced encephalopathy during the treatment of African trypanosomiasis. Apropos of a case with a favorable outcome]. Pialoux G; Kernbaum S; Vachon F Bull Soc Pathol Exot Filiales; 1988; 81(3 Pt 2):555-6. PubMed ID: 3197251 [TBL] [Abstract][Full Text] [Related]
10. Randomized controlled trial of three regimens of melarsoprol in the treatment of Trypanosoma brucei gambiense trypanosomiasis. Pépin J; Mpia B Trans R Soc Trop Med Hyg; 2006 May; 100(5):437-41. PubMed ID: 16483622 [TBL] [Abstract][Full Text] [Related]
11. The importance of 2,3-dimercaptopropinol (British anti-lewisite, BAL) in the trypanocidal activity of topical melarsoprol. Jennings FW; Atouguia JM; Murray M Acta Trop; 1996 Oct; 62(2):83-9. PubMed ID: 8988309 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Burri C; Nkunku S; Merolle A; Smith T; Blum J; Brun R Lancet; 2000 Apr; 355(9213):1419-25. PubMed ID: 10791526 [TBL] [Abstract][Full Text] [Related]
13. Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. Chappuis F; Udayraj N; Stietenroth K; Meussen A; Bovier PA Clin Infect Dis; 2005 Sep; 41(5):748-51. PubMed ID: 16080099 [TBL] [Abstract][Full Text] [Related]
14. Trypanosoma brucei brucei: the response to Melarsoprol in mice with cerebral trypanosomiasis. An immunopathological study. Poltera AA; Hochmann A; Lambert PH Clin Exp Immunol; 1981 Nov; 46(2):363-74. PubMed ID: 7039886 [TBL] [Abstract][Full Text] [Related]
15. An alternative form of melarsoprol in sleeping sickness. Kennedy PG Trends Parasitol; 2012 Aug; 28(8):307-10. PubMed ID: 22704910 [TBL] [Abstract][Full Text] [Related]
16. Combination chemotherapy with a substance P receptor antagonist (aprepitant) and melarsoprol in a mouse model of human African trypanosomiasis. Rodgers J; Bradley B; Kennedy PG Parasitol Int; 2007 Dec; 56(4):321-4. PubMed ID: 17643344 [TBL] [Abstract][Full Text] [Related]
17. Eflornithine for the treatment of human African trypanosomiasis. Burri C; Brun R Parasitol Res; 2003 Jun; 90 Supp 1():S49-52. PubMed ID: 12811548 [TBL] [Abstract][Full Text] [Related]
18. Human African trypanosomiasis: diagnosis, relapse and survival after severe melarsoprol-induced encephalopathy. Checkley AM; Pepin J; Gibson WC; Taylor MN; Jäger HR; Mabey DC Trans R Soc Trop Med Hyg; 2007 May; 101(5):523-6. PubMed ID: 17270227 [TBL] [Abstract][Full Text] [Related]
19. Current chemotherapy of human African trypanosomiasis. Docampo R; Moreno SN Parasitol Res; 2003 Jun; 90 Supp 1():S10-3. PubMed ID: 12811544 [TBL] [Abstract][Full Text] [Related]
20. Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda. Matovu E; Enyaru JC; Legros D; Schmid C; Seebeck T; Kaminsky R Trop Med Int Health; 2001 May; 6(5):407-11. PubMed ID: 11348535 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]